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According to the findings of the National Vital Statistics
Report and the Morbidity and Mortality Weekly report of the
Centers for Disease Control and Prevention (CDC), cardiovascu-
lar disease continues to rank high among the leading causes of
morbidity and mortality in adults in the United States. It is well
known that most Americans are overfed and under-exercised, but
what is much less well-known is how bad nutrition is causing an
alarming increase in the frequency of obesity, heart disease, stroke,
cancer, diabetes, and even dementia. Several epidemiological stud-
ies suggest that dietary patterns characterized by relatively high
intake of fruits and vegetables are significantly associated with
reduced risks of coronary heart disease and stroke. These foods
have phytochemicals including carotenoids, and polyphenols like
flavonoids, resveratrol and ellagitannins, iosthiocyanates and orga-
nosulfur compounds, each of which has been shown to be associ-
ated with lower risk of cardiovascular disease. Phytochemicals are
potent antioxidants and anti-inflammatory agents, thereby coun-
teracting oxidative damage and inflammation, which underlie the
pathogenesis of cardiovascular disease. The authors present more
data showing the importance of a diet high in polyphenols such as
ellagic acid (ellagitannins). The authors show for the first time that
pretreatment of endothelial cells with ellagic acid protected againstmediated signaling pathway. The proatherosclerotic role of LOX-1
was made clear by Mehta and Sawamura when they reported that a
LOX-1 knockout mouse model had reduced formation of athero-
sclerotic lesions in a proatherogenic genetic background under a
high-cholesterol diet. Proatherosclerotic and pro-oxidative signal-
ing and inflammatory response were measured as vascular NF-B,
CD68 expression, and p38 MAPK activation. Endothelial cell
function was preserved, therefore providing proof of concept that
LOX-1 was proatherosclerotic. There is evidence of LOX-1-
increased expression in atherosclerotic plaques from human sam-
ples. There are also interesting studies showing that patients re-
ceiving ACE inhibitors and statins (Endothelial Protection, AT1
blockage and Cholesterol-Dependent Oxidative Stress [EPAS]
trial) independently and in combination had improved endothelial
expression quotient of anti- and proatherosclerotic genes such as
LOX-1. Further of interest is a small randomized controlled trial
involving 19 patients with carotid artery stenosis found that pome-
granate juice, high in ellagic acid, appeared to rescue blood pres-
sure and carotid wall thickness. Inhibition of LOX-1 might be an
interesting and novel therapeutic strategy in the treatment of
atherosclerosis. One might even postulate from the authors’ work
that a diet high in polyphenols, especially ellagic acid, could lead to
prevention of atherosclerotic disease or even regression.
